TWI750725B - 新穎脂肪酸及其於共軛至生物分子之用途 - Google Patents

新穎脂肪酸及其於共軛至生物分子之用途 Download PDF

Info

Publication number
TWI750725B
TWI750725B TW109123095A TW109123095A TWI750725B TW I750725 B TWI750725 B TW I750725B TW 109123095 A TW109123095 A TW 109123095A TW 109123095 A TW109123095 A TW 109123095A TW I750725 B TWI750725 B TW I750725B
Authority
TW
Taiwan
Prior art keywords
conjugate
acid
mmol
peptide
gdf15
Prior art date
Application number
TW109123095A
Other languages
English (en)
Chinese (zh)
Other versions
TW202039004A (zh
Inventor
大衛 溫英傑 伯尼斯
山田健
去克溫杜 伊比邦久
阿洛克許 都塔羅伊
路易斯 克萊爾 可曼
亞立山卓 馬歇爾 布魯斯
愛咪 瑞察德森 優瑟拉
佛瑞德利克 查克利
強 元
樓長剛
艾倫 肯特
愛薇洛普 博斯
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI750725(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202039004A publication Critical patent/TW202039004A/zh
Application granted granted Critical
Publication of TWI750725B publication Critical patent/TWI750725B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
TW109123095A 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途 TWI750725B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US62/015,862 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US62/082,327 2014-11-20
US201562107016P 2015-01-23 2015-01-23
US62/107,016 2015-01-23

Publications (2)

Publication Number Publication Date
TW202039004A TW202039004A (zh) 2020-11-01
TWI750725B true TWI750725B (zh) 2021-12-21

Family

ID=53491695

Family Applications (3)

Application Number Title Priority Date Filing Date
TW109123095A TWI750725B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途
TW104120074A TWI701048B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途
TW110136772A TWI792596B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW104120074A TWI701048B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途
TW110136772A TWI792596B (zh) 2014-06-23 2015-06-22 新穎脂肪酸及其於共軛至生物分子之用途

Country Status (36)

Country Link
US (4) US10588980B2 (enExample)
EP (2) EP3157571B1 (enExample)
JP (5) JP6636959B2 (enExample)
KR (2) KR102559975B1 (enExample)
CN (3) CN114133443A (enExample)
AP (1) AP2016009585A0 (enExample)
AU (1) AU2015280351C1 (enExample)
CA (1) CA2953480A1 (enExample)
CL (1) CL2016003281A1 (enExample)
CR (1) CR20160596A (enExample)
CU (1) CU24455B1 (enExample)
CY (1) CY1125006T1 (enExample)
DK (1) DK3157571T3 (enExample)
EA (1) EA039074B1 (enExample)
EC (1) ECSP17004665A (enExample)
ES (1) ES2905479T3 (enExample)
GT (1) GT201600263A (enExample)
HR (1) HRP20220152T1 (enExample)
HU (1) HUE057845T2 (enExample)
IL (1) IL248990B (enExample)
JO (1) JO3813B1 (enExample)
LT (1) LT3157571T (enExample)
MA (1) MA40278A (enExample)
MX (1) MX367520B (enExample)
MY (1) MY193993A (enExample)
PE (1) PE20171095A1 (enExample)
PH (1) PH12016502294B1 (enExample)
PL (1) PL3157571T3 (enExample)
PT (1) PT3157571T (enExample)
RS (1) RS62907B1 (enExample)
SG (2) SG11201609704TA (enExample)
SI (1) SI3157571T1 (enExample)
TN (1) TN2016000558A1 (enExample)
TW (3) TWI750725B (enExample)
UY (1) UY36186A (enExample)
WO (1) WO2015200078A1 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MX2017007303A (es) 2014-12-04 2017-08-25 Novartis Ag Metodos y composiciones que utilizan polipeptidos variantes klotho.
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JP6892433B2 (ja) 2015-04-03 2021-06-23 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 十分に安定化された非対称ｓｉｒｎａ
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
CN108367053A (zh) * 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
AU2017210726B2 (en) 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
AU2017269496B2 (en) 2016-05-24 2021-03-25 Novo Nordisk A/S MIC-1 compounds and use thereof
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
CN110446785B (zh) 2017-01-23 2024-04-26 瑞泽恩制药公司 Hsd17b13变体及其应用
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
ES2867807T3 (es) 2017-04-24 2021-10-20 Igm Group B V Proceso para la preparación de cetonas a-funcionalizadas
MX2019013693A (es) * 2017-05-18 2020-01-27 Regeneron Pharma Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
US10961583B2 (en) 2017-10-11 2021-03-30 Regeneron Phramaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
LT3727423T (lt) 2017-12-22 2024-07-10 Novartis Ag Metabolinių sutrikimų gydymas fgf21 variantais
CA3091146A1 (en) 2018-03-21 2019-09-26 Regeneron Pharmaceuticals, Inc. 17.beta.-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CR20200510A (es) 2018-04-09 2020-11-26 Amgen Inc Protreínas de fusión del factor de diferenciación de crecimiento 15
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
AU2019316640A1 (en) 2018-08-10 2021-03-18 University Of Massachusetts Modified oligonucleotides targeting SNPs
CN112543869A (zh) 2018-08-10 2021-03-23 诺华股份有限公司 Gfral细胞外结构域和使用方法
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
TWI856973B (zh) * 2018-09-19 2024-10-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CN113226351B (zh) 2018-10-22 2025-01-14 詹森药业有限公司 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途
CN113396158A (zh) 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
US11492619B2 (en) 2019-01-18 2022-11-08 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
KR20200124176A (ko) * 2019-04-23 2020-11-02 주식회사 엘지화학 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
US11746354B2 (en) 2019-07-19 2023-09-05 Inari Agriculture Technology, Inc. Homology dependent repair genome editing
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
EP4025252A4 (en) * 2019-09-03 2023-10-18 Arcturus Therapeutics, Inc. ASIALOGLYCOPROTEIN RECEPTOR-MEDIATED ADMINISTRATION OF THERAPEUTICALLY ACTIVE CONJUGATES
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CA3142709A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
CN115397471A (zh) * 2019-11-26 2022-11-25 Dtx医药有限公司 包括核酸和半衰期延长基序的化合物
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
JP2023509991A (ja) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
EP4090376A1 (en) * 2020-01-13 2022-11-23 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
JP2023510850A (ja) * 2020-01-13 2023-03-15 シンアフィックス ビー．ブイ． 付加環化を介して両側官能化された抗体
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
EP4351628A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT
MX2023015523A (es) 2021-06-23 2024-03-11 Univ Massachusetts Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogenicos.
EP4398939A1 (en) * 2021-09-10 2024-07-17 Guardian Therapeutics, LLC Fatty acid conjugates of nucleic acids
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
TW202342014A (zh) 2022-02-10 2023-11-01 瑞士商諾華公司 １，３－苯并二氧戊環衍生物
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for reducing or preventing tissue fibrosis
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
WO2024030367A2 (en) * 2022-08-01 2024-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acid-d-amino acid peptides conjugates as anaplerotic compounds for use in treating propionic acidemia, methylmalonic acidurias, and energy metabolic disorders
CN115575539B (zh) * 2022-10-12 2025-04-18 南方医科大学珠江医院 一种生物标本中短链脂肪酸及其羟基化衍生物的检测方法
CN116789764B (zh) * 2023-05-30 2025-01-03 北京悦康科创医药科技股份有限公司 一种抗冠状病毒多肽的制备方法
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法
WO2025049634A1 (en) * 2023-08-29 2025-03-06 Ganna Bio, Inc. Glycan conjugate compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (en) * 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
GB2124618A (en) 1982-06-11 1984-02-22 Nat Res Dev Aliphatic hydroxy amides
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP0492628B1 (en) 1990-12-26 1996-07-03 Ricoh Company, Ltd Reversible thermosensitive coloring composition, recording medium, recording method and image display apparatus using the recording medium
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
ES2324433T3 (es) 1995-06-22 2009-08-06 St Vincent's Hospital Sydney Limited Tgf-beta novedoso similar a citocina.
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
BR9711763A (pt) 1996-09-11 1999-08-24 Ortho Mcneil Pharm Inc Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
CN1283228A (zh) 1997-12-24 2001-02-07 武田药品工业株式会社 多肽、其生产方法及应用
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
US20020045170A1 (en) 2000-04-06 2002-04-18 Wong Gordon G. Polynucleotides encoding novel secreted proteins
CA2405680C (en) 2000-04-20 2018-02-13 St. Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
WO2004103995A1 (en) 2003-05-20 2004-12-02 Novartis Ag N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2005205595A1 (en) 2004-01-14 2005-07-28 Janssen Pharmaceutica N.V. Methods of using peroxisome proliferator-activated receptor alpha target genes
SI2441466T1 (sl) 2004-04-13 2015-01-30 St Vincent's Hospital Sydney Limited Centre For Immunology Sredstvo, ki inhibira MIC-1
US20070207120A1 (en) 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
WO2006117240A2 (en) 2005-04-29 2006-11-09 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN101405293B (zh) 2005-11-30 2013-03-13 中裕新药股份有限公司 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法
CN101378773B (zh) 2005-12-20 2013-03-13 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
JP2010536717A (ja) 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
US20100310504A1 (en) 2007-09-26 2010-12-09 Lowe Scott W Methods for treating fibrosis by modulating cellular senescence
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8673841B2 (en) 2008-03-31 2014-03-18 Ferring B.V. Oxytocin analogues
AU2009308163B2 (en) 2008-10-24 2013-01-10 Novartis Ag Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
WO2010052144A2 (en) * 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20130053433A1 (en) 2010-01-06 2013-02-28 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
ES2527536T7 (es) 2010-04-27 2016-03-08 Synaffix B.V. Compuestos de ciclooctina fusionada y su uso en reacciones clic sin metales
BR112012027256A2 (pt) * 2010-04-27 2015-09-22 Syngenta Participations Ag métodos de controle de afídeos resistentes a neonicotinoides
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
WO2013006656A2 (en) 2011-07-05 2013-01-10 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
WO2013130683A2 (en) 2012-02-27 2013-09-06 Amunix Operating Inc. Xten conjugate compositions and methods of making same
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
BR112015014010A2 (pt) 2012-12-21 2017-07-11 Hoffmann La Roche peptídeos como agonistas oxitocina
EP2934584B1 (en) 2012-12-21 2020-02-19 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
SI2981822T1 (sl) 2013-05-06 2021-08-31 Scholar Rock, Inc. Sestavki in postopki za modulacijo rastnega dejavnika
EP3016684B1 (en) 2013-07-03 2022-02-23 H. Lundbeck A/S Regulation of glucose metabolism using anti-cgrp antibodies
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
EP3024847A1 (en) 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013165A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic apelin derivatives for the treatment of heart failure
EA037355B1 (ru) 2013-07-31 2021-03-17 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf-15)
WO2015079376A1 (en) 2013-11-26 2015-06-04 Novartis Ag Methods for oxime conjugation to ketone-modified polypeptides
EP3102703A2 (en) 2014-02-07 2016-12-14 Effector Therapeutics Inc. Methods for treating fibrotic disease
CN106461830B (zh) 2014-05-01 2019-08-27 富士胶片株式会社 红外线传感器、近红外线吸收组合物、感光性树脂组合物、化合物及其应用
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
JP6768527B2 (ja) 2014-06-20 2020-10-14 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
ES2818109T3 (es) 2014-06-23 2021-04-09 Novartis Ag Modificaciones de proteínas específicas para un sitio
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
EP3922259A1 (en) 2014-10-30 2021-12-15 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
ES2799503T3 (es) 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
EP3237440A1 (en) 2014-12-22 2017-11-01 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PL3280727T3 (pl) 2015-04-06 2021-07-19 Acceleron Pharma Inc. Jednoramienne białka fuzyjne receptora typu I i typu II i ich zastosowania
AU2016244750B2 (en) 2015-04-06 2021-02-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
US20200237923A1 (en) 2015-10-14 2020-07-30 The Johns Hopkins University Protein bioconjugation method
CN108367053A (zh) 2015-12-22 2018-08-03 诺华股份有限公司 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
JP2019513224A (ja) 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス，インコー 体重を調節するための組成物及び方法
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
MA50141A (fr) 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
EP4041281B1 (en) 2019-10-04 2025-11-26 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
EP4135750A4 (en) 2020-04-15 2024-08-21 Theradaptive, Inc. COMPOSITIONS AND METHODS FOR TARGETED THERAPEUTIC RELEASE IN BONE
WO2022092915A1 (ko) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083505A1 (en) * 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins

Also Published As

Publication number Publication date
AU2015280351B2 (en) 2018-07-05
JP7650315B2 (ja) 2025-03-24
CY1125006T1 (el) 2023-01-05
CL2016003281A1 (es) 2017-06-09
KR102559975B1 (ko) 2023-07-27
AP2016009585A0 (en) 2016-11-30
CN114099693A (zh) 2022-03-01
US11752211B2 (en) 2023-09-12
JP2023099133A (ja) 2023-07-11
JP6636959B2 (ja) 2020-01-29
EA039074B1 (ru) 2021-11-30
WO2015200078A1 (en) 2015-12-30
IL248990B (en) 2019-09-26
MA40278A (fr) 2017-04-26
JP2022095757A (ja) 2022-06-28
SG10201912965TA (en) 2020-02-27
PL3157571T3 (pl) 2022-03-28
HRP20220152T1 (hr) 2022-04-15
EP3988170A1 (en) 2022-04-27
US20240066132A1 (en) 2024-02-29
CA2953480A1 (en) 2015-12-30
ECSP17004665A (es) 2018-11-30
PT3157571T (pt) 2022-02-14
MX2016017395A (es) 2017-05-01
UY36186A (es) 2016-01-29
DK3157571T3 (da) 2022-02-21
JP2019206563A (ja) 2019-12-05
ES2905479T3 (es) 2022-04-08
TW201613653A (en) 2016-04-16
US20160030585A1 (en) 2016-02-04
SI3157571T1 (sl) 2022-04-29
TW202039004A (zh) 2020-11-01
MY193993A (en) 2022-11-07
KR20230056796A (ko) 2023-04-27
CN107073130A (zh) 2017-08-18
JP6823696B2 (ja) 2021-02-03
IL248990A0 (en) 2017-01-31
EA201692466A1 (ru) 2017-04-28
LT3157571T (lt) 2022-02-25
PH12016502294B1 (en) 2022-03-23
JP2020203934A (ja) 2020-12-24
MX367520B (es) 2019-08-26
EP3157571A1 (en) 2017-04-26
CU24455B1 (es) 2019-11-04
US10786576B2 (en) 2020-09-29
RS62907B1 (sr) 2022-03-31
TN2016000558A1 (en) 2018-04-04
PE20171095A1 (es) 2017-08-07
CN114133443A (zh) 2022-03-04
CN107073130B (zh) 2021-11-16
JP2017519024A (ja) 2017-07-13
GT201600263A (es) 2019-07-19
JP7051959B2 (ja) 2022-04-11
HK1232160A1 (zh) 2018-01-05
EP3157571B1 (en) 2021-11-24
HUE057845T2 (hu) 2022-06-28
AU2015280351A1 (en) 2016-12-08
SG11201609704TA (en) 2017-01-27
JO3813B1 (ar) 2021-01-31
BR112016028884A2 (pt) 2017-10-31
US20210000964A1 (en) 2021-01-07
TWI701048B (zh) 2020-08-11
US10588980B2 (en) 2020-03-17
TW202204384A (zh) 2022-02-01
TWI792596B (zh) 2023-02-11
WO2015200078A8 (en) 2016-04-14
CR20160596A (es) 2017-05-08
US20180326079A1 (en) 2018-11-15
CU20160189A7 (es) 2017-04-05
KR20170020878A (ko) 2017-02-24
PH12016502294A1 (en) 2017-02-13
AU2015280351C1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP7650315B2 (ja) 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用
KR102310392B1 (ko) 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CA3014641C (en) Insulin receptor partial agonists
KR102394515B1 (ko) 아실화된 글루카곤 유사체
ES2963839T3 (es) Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
KR20160031551A (ko) 심부전의 치료를 위한 시클릭 폴리펩티드
HK40072273A (en) Fatty acids and their use in conjugation to biomolecules
BR112016028884B1 (pt) Conjugado compreendendo uma biomolécula ligada a um ácido graxo, seu uso, mistura, combinação, composição farmacêutica, e composto
WO2025070731A1 (ja) ペプチド
HK1232160B (en) Fatty acids and their use in conjugation to biomolecules